Tardive dyskinesia syndromes: current concepts
- PMID: 24262160
- DOI: 10.1016/S1353-8020(13)70028-2
Tardive dyskinesia syndromes: current concepts
Abstract
Tardive syndromes (TS) encompass a broad spectrum of abnormal movements due to chronic exposure to dopamine receptor blocking agents. This review provides a compiled update on TS, including phenomenology, epidemiology, pathophysiology, genetic correlations and therapeutics, highlighting the emerging experience with atypical antipsychotics. The advent of atypical antipsychotics, which have lower affinity for dopamine receptors and act on 5-HT2A and 5-HT2C serotonin receptors, was expected to dramatically reduce the prevalence and incidence of this iatrogenic problem. Recent studies have shown that the reduction has been more modest than expected and TS remains an important challenge. Recent insights on pathophysiology, risk factors and genetic correlations have raised the hope for further individualized treatment for schizophrenic patients, and more strict use of antipsychotics. Up to now, there is no definite treatment for TS, but options range from relatively innocuous low doses of propranolol to more invasive procedures such as deep brain stimulation.
Keywords: Antipsychotics; Tardive dyskinesia; Tardive syndrome.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Epidemiology and risk factors for (tardive) dyskinesia.Int Rev Neurobiol. 2011;98:211-30. doi: 10.1016/B978-0-12-381328-2.00009-2. Int Rev Neurobiol. 2011. PMID: 21907089 Review.
-
Spectrum of tardive syndromes: clinical recognition and management.Postgrad Med J. 2011 Feb;87(1024):132-41. doi: 10.1136/pgmj.2010.103234. Epub 2010 Dec 3. Postgrad Med J. 2011. PMID: 21131613 Review.
-
Atypical antipsychotics: mechanism of action.Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review.
-
Classification and treatment of tardive syndromes.Neurologist. 2003 Jan;9(1):16-27. doi: 10.1097/01.nrl.0000038585.58012.97. Neurologist. 2003. PMID: 12801428 Review.
-
Tardive syndrome: An update and mini-review from the perspective of phenomenology.J Chin Med Assoc. 2020 Dec;83(12):1059-1065. doi: 10.1097/JCMA.0000000000000435. J Chin Med Assoc. 2020. PMID: 32956105
Cited by
-
[Antipsychotic-induced tardive syndromes].Neuropsychiatr. 2016 Sep;30(3):123-130. doi: 10.1007/s40211-016-0189-7. Epub 2016 Aug 31. Neuropsychiatr. 2016. PMID: 27580887 Review. German.
-
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.CNS Drugs. 2018 Feb;32(2):135-147. doi: 10.1007/s40263-018-0494-8. CNS Drugs. 2018. PMID: 29427000 Review.
-
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.Front Neurol. 2022 Feb 23;13:773999. doi: 10.3389/fneur.2022.773999. eCollection 2022. Front Neurol. 2022. PMID: 35280262 Free PMC article.
-
Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.Front Psychiatry. 2016 Dec 26;7:207. doi: 10.3389/fpsyt.2016.00207. eCollection 2016. Front Psychiatry. 2016. PMID: 28082923 Free PMC article. Review.
-
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26. Neurology. 2017. PMID: 28446646 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
